Literature DB >> 3140966

Treatment with cyclosporin and risks of graft rejection in male kidney and heart transplant recipients with non-O blood.

G F Hendriks1, E P van Steenberge, G M Schreuder, G J Wenting, B Mochtar, E Bos, M L Simoons, A H Balk, K Laird-Meeter, C E Essed.   

Abstract

In a consecutive series of 146 kidney transplant recipients treated with cyclosporin A a strong correlation between matching for the HLA-A, HLA-B, and HLA-DR loci specificities and outcome of the grafts was observed in male recipients with non-O blood groups. Such a beneficial effect of matching was not found in female patients or male patients with blood group O. In these patients survival of the grafts at one year was good irrespective of the number of HLA-A, B, and DR mismatches. Also in 47 male heart transplant recipients immune responsiveness against mismatched HLA antigens was related to blood group. A significantly higher incidence of rejection episodes was observed in male patients with non-O blood groups (n = 32) than in those with blood group O (n = 15). Matching for HLA-DR reduced the number of acute rejection episodes in male patients with non-O blood. These findings may help explain the controversial reports about the importance of HLA matching in organ transplantation. Furthermore, as most candidates for heart transplantation are male and not of blood group O, the higher incidence of graft rejection in these patients underscores the need for an exchange strategy of donor hearts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140966      PMCID: PMC1834453          DOI: 10.1136/bmj.297.6653.888

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  23 in total

1.  Differential kidney graft survival associated with interaction between recipient ABO group and pretransplant blood transfusion.

Authors:  V C Joysey; J H Roger; D B Evans; B M Herbertson
Journal:  Transplantation       Date:  1977-11       Impact factor: 4.939

2.  An eight-year study of HLA typing proficiency in Eurotransplant.

Authors:  G M Schreuder; G F Hendriks; J D'Amaro; G G Persijn
Journal:  Tissue Antigens       Date:  1986-03

3.  Eurotransplant experience with highly immunized patients.

Authors:  G F Hendriks; P de Lange; J D'Amaro; G M Schreuder; F H Claas; G G Persijn; J J van Rood
Journal:  Scand J Urol Nephrol Suppl       Date:  1985

4.  CML nonreactivity after kidney transplantation.

Authors:  E Goulmy; G G Persijn; E Blokland; J J van Rood
Journal:  Transplant Proc       Date:  1981-09       Impact factor: 1.066

5.  Long-term follow-up in London Transplant Group recipients of cadaver renal allografts. The influence of HLA matching on transplant outcome.

Authors:  H Festenstein; P Doyle; J Holmes
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

6.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

7.  Importance of HLA-DR matching in polytransfused cadaveric kidney transplant recipients. A prospective one-center study.

Authors:  Y Vanrenterghem; I Vandeputte; T Lerut; L Roels; J Gruwez; P Michielsen
Journal:  Transplantation       Date:  1983-10       Impact factor: 4.939

8.  Powerful effect of HL-DR matching on survival of cadaveric renal allografts.

Authors:  A Ting; P J Morris
Journal:  Lancet       Date:  1980-08-09       Impact factor: 79.321

9.  Matching for HLA antigens of A, B, and DR loci in renal transplantation by Eurotransplant.

Authors:  G G Persijn; B W Gabb; A van Leeuwen; A Nagtegaal; J Hoogeboom; J J van Rood
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

10.  Importance of HLA-DR matching in cadaveric renal transplantation: a prospective one-center study of 170 transplants.

Authors:  T Moen; D Albrechtsen; A Flatmark; A Jakobsen; J Jervell; S Halvorsen; B G Solheim; E Thorsby
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.